STOK · Stoke Therapeutics, Inc.
$25.04
-2.57% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-7.1
Dividend yield
0.0%
Beta
1.26
Avg volume
1M
Employees
0K
Daily Change %
-2.57%
5 Days Change
6.33%
10 Days Change
14.22%
30 Days Change
-1.57%
60 Days Change
-20.48%
Month to Day Change
-1.19%
Year to Day Change
-19.03%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — STOK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-04
Latest call per bank · past 12 months
Goldman Sachs
Buy$44.00
+75.7% vs priceJP Morgan
Neutral$25.00
-0.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Guggenheim | Reiterates | Buy | $60.00 |
| 2026-08-04 | Wedbush | Maintains | Outperform | $38.00 → $40.00 |
| 2026-08-04 | Canaccord Genuity | Maintains | Buy | $60.00 → $58.00 |
| 2026-08-04 | Chardan Capital | Maintains | Buy | $35.00 |
| 2026-07-13 | Goldman Sachs | Initiates | Buy | $0.00 → $44.00 |
| 2026-05-11 | BTIG | Reiterates | Buy | $39.00 |
| 2026-03-20 | Canaccord Genuity | Maintains | Buy | $36.00 → $60.00 |
| 2026-03-19 | BTIG | Reiterates | Buy | $39.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.6% below the 50-day MA ($28.02).
- bearish: Price vs 200-day MA: Trading 19.4% below the 200-day MA ($31.05).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.35) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($22.37) and high ($38.35).
STOK Price Chart
Loading chart for STOK…
Fundamentals
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.